Immunic, inc. publishes positive results from the single and multiple ascending dose parts of its phase 1 clinical trial of imu-935, a potentially best-in-class oral il-17 inhibitor

New york, dec. 14, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced positive unblinded safety, tolerability and pharmacokinetic (pk) results from part a (single ascending doses, sad) and part b (multiple ascending doses, mad) of its phase 1 clinical trial of imu-935 in healthy human subjects. in addition, the company announced newly available preclinical in vivo data showing that imu-935 maintains normal thymocyte maturation in relevant acute and chronic mouse models.
IMUX Ratings Summary
IMUX Quant Ranking